NEW YORK – (AP) Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.
Late Monday, a jury in the Eastern District of Texas found that Abbott's best-selling drug, Humira, violated a patent on Johnson & Johnson's . . . .
Subscribers to www.lexis.com may read the full version of this article here.